Celldex to host a webcast/conference call on Monday, November 25, 2013
at 8:30 am ET
Celldex's CDX-301 in Combination with Mozobil(R) Increases Hematopoietic Stem Cell Mobilization and Results in Improved Transplantation of Mobilized Cells in Preclinical Studies; Results Presented at ASH 2013
Tue, 10 Dec 2013
Mon, 09 Dec 2013
Wed, 04 Dec 2013
Tue, 03 Dec 2013
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.